216 related articles for article (PubMed ID: 37315889)
1. Protective effects of the succinate/SUCNR1 axis on damaged hepatocytes in NAFLD.
Marsal-Beltran A; Rodríguez-Castellano A; Astiarraga B; Calvo E; Rada P; Madeira A; Rodríguez-Peña MM; Llauradó G; Núñez-Roa C; Gómez-Santos B; Maymó-Masip E; Bosch R; Frutos MD; Moreno-Navarrete JM; Ramos-Molina B; Aspichueta P; Joven J; Fernández-Real JM; Quer JC; Valverde ÁM; Pardo A; Vendrell J; Ceperuelo-Mallafré V; Fernández-Veledo S
Metabolism; 2023 Aug; 145():155630. PubMed ID: 37315889
[TBL] [Abstract][Full Text] [Related]
2. Necroptosis is a key pathogenic event in human and experimental murine models of non-alcoholic steatohepatitis.
Afonso MB; Rodrigues PM; Carvalho T; Caridade M; Borralho P; Cortez-Pinto H; Castro RE; Rodrigues CM
Clin Sci (Lond); 2015 Oct; 129(8):721-39. PubMed ID: 26201023
[TBL] [Abstract][Full Text] [Related]
3. Tcf7l2 in hepatocytes regulates de novo lipogenesis in diet-induced non-alcoholic fatty liver disease in mice.
Lee DS; An TH; Kim H; Jung E; Kim G; Oh SY; Kim JS; Chun HJ; Jung J; Lee EW; Han BS; Han DH; Lee YH; Han TS; Hur K; Lee CH; Kim DS; Kim WK; Park JW; Koo SH; Seong JK; Lee SC; Kim H; Bae KH; Oh KJ
Diabetologia; 2023 May; 66(5):931-954. PubMed ID: 36759348
[TBL] [Abstract][Full Text] [Related]
4. Fatty acids in non-alcoholic steatohepatitis: Focus on pentadecanoic acid.
Yoo W; Gjuka D; Stevenson HL; Song X; Shen H; Yoo SY; Wang J; Fallon M; Ioannou GN; Harrison SA; Beretta L
PLoS One; 2017; 12(12):e0189965. PubMed ID: 29244873
[TBL] [Abstract][Full Text] [Related]
5. Thrombospondin-I is a critical modulator in non-alcoholic steatohepatitis (NASH).
Min-DeBartolo J; Schlerman F; Akare S; Wang J; McMahon J; Zhan Y; Syed J; He W; Zhang B; Martinez RV
PLoS One; 2019; 14(12):e0226854. PubMed ID: 31891606
[TBL] [Abstract][Full Text] [Related]
6. Hepatocyte-specific activity of TSC22D4 triggers progressive NAFLD by impairing mitochondrial function.
Wolff G; Sakurai M; Mhamane A; Troullinaki M; Maida A; Deligiannis IK; Yin K; Weber P; Morgenstern J; Wieder A; Kwon Y; Sekar R; Zeigerer A; Roden M; Blüher M; Volk N; Poth T; Hackert T; Wiedmann L; De Angelis Rigotti F; Rodriguez-Vita J; Fischer A; Mukthavaram R; Limphong P; Tachikawa K; Karmali P; Payne J; Chivukula P; Ekim-Üstünel B; Martinez-Jimenez CP; Szendrödi J; Nawroth P; Herzig S
Mol Metab; 2022 Jun; 60():101487. PubMed ID: 35378329
[TBL] [Abstract][Full Text] [Related]
7. Perilipin-2 promotes obesity and progressive fatty liver disease in mice through mechanistically distinct hepatocyte and extra-hepatocyte actions.
Orlicky DJ; Libby AE; Bales ES; McMahan RH; Monks J; La Rosa FG; McManaman JL
J Physiol; 2019 Mar; 597(6):1565-1584. PubMed ID: 30536914
[TBL] [Abstract][Full Text] [Related]
8. Involvement of G protein-coupled receptor kinase 2 (GRK2) in the development of non-alcoholic steatosis and steatohepatitis in mice and humans.
Cruces-Sande M; Vila-Bedmar R; Arcones AC; González-Rodríguez Á; Rada P; Gutiérrez-de-Juan V; Vargas-Castrillón J; Iruzubieta P; Sánchez-González C; Formentini L; Crespo J; García-Monzón C; Martínez-Chantar ML; Valverde ÁM; Mayor F; Murga C
Biochim Biophys Acta Mol Basis Dis; 2018 Dec; 1864(12):3655-3667. PubMed ID: 30261289
[TBL] [Abstract][Full Text] [Related]
9. A Comparison of the Gene Expression Profiles of Non-Alcoholic Fatty Liver Disease between Animal Models of a High-Fat Diet and Methionine-Choline-Deficient Diet.
Alshawsh MA; Alsalahi A; Alshehade SA; Saghir SAM; Ahmeda AF; Al Zarzour RH; Mahmoud AM
Molecules; 2022 Jan; 27(3):. PubMed ID: 35164140
[TBL] [Abstract][Full Text] [Related]
10. Inhibition of receptor-interacting protein kinase 1 improves experimental non-alcoholic fatty liver disease.
Majdi A; Aoudjehane L; Ratziu V; Islam T; Afonso MB; Conti F; Mestiri T; Lagouge M; Foufelle F; Ballenghien F; Ledent T; Moldes M; Cadoret A; Fouassier L; Delaunay JL; Aït-Slimane T; Courtois G; Fève B; Scatton O; Prip-Buus C; Rodrigues CMP; Housset C; Gautheron J
J Hepatol; 2020 Apr; 72(4):627-635. PubMed ID: 31760070
[TBL] [Abstract][Full Text] [Related]
11. Hepatocyte vitamin D receptor regulates lipid metabolism and mediates experimental diet-induced steatosis.
Bozic M; Guzmán C; Benet M; Sánchez-Campos S; García-Monzón C; Gari E; Gatius S; Valdivielso JM; Jover R
J Hepatol; 2016 Oct; 65(4):748-757. PubMed ID: 27245430
[TBL] [Abstract][Full Text] [Related]
12. Inhibiting Interleukin 11 Signaling Reduces Hepatocyte Death and Liver Fibrosis, Inflammation, and Steatosis in Mouse Models of Nonalcoholic Steatohepatitis.
Widjaja AA; Singh BK; Adami E; Viswanathan S; Dong J; D'Agostino GA; Ng B; Lim WW; Tan J; Paleja BS; Tripathi M; Lim SY; Shekeran SG; Chothani SP; Rabes A; Sombetzki M; Bruinstroop E; Min LP; Sinha RA; Albani S; Yen PM; Schafer S; Cook SA
Gastroenterology; 2019 Sep; 157(3):777-792.e14. PubMed ID: 31078624
[TBL] [Abstract][Full Text] [Related]
13. Enhanced expression of BMP6 inhibits hepatic fibrosis in non-alcoholic fatty liver disease.
Arndt S; Wacker E; Dorn C; Koch A; Saugspier M; Thasler WE; Hartmann A; Bosserhoff AK; Hellerbrand C
Gut; 2015 Jun; 64(6):973-81. PubMed ID: 25011936
[TBL] [Abstract][Full Text] [Related]
14. The transcription factor c-Jun/AP-1 promotes liver fibrosis during non-alcoholic steatohepatitis by regulating Osteopontin expression.
Schulien I; Hockenjos B; Schmitt-Graeff A; Perdekamp MG; Follo M; Thimme R; Hasselblatt P
Cell Death Differ; 2019 Sep; 26(9):1688-1699. PubMed ID: 30778201
[TBL] [Abstract][Full Text] [Related]
15. Thrombospondin 1 improves hepatic steatosis in diet-induced insulin-resistant mice and is associated with hepatic fat content in humans.
Bai J; Xia M; Xue Y; Ma F; Cui A; Sun Y; Han Y; Xu X; Zhang F; Hu Z; Liu Z; Liu Y; Cai G; Su W; Sun X; Wu H; Yan H; Chang X; Hu X; Bian H; Xia P; Gao J; Li Y; Gao X
EBioMedicine; 2020 Jul; 57():102849. PubMed ID: 32580141
[TBL] [Abstract][Full Text] [Related]
16. CD44 is a key player in non-alcoholic steatohepatitis.
Patouraux S; Rousseau D; Bonnafous S; Lebeaupin C; Luci C; Canivet CM; Schneck AS; Bertola A; Saint-Paul MC; Iannelli A; Gugenheim J; Anty R; Tran A; Bailly-Maitre B; Gual P
J Hepatol; 2017 Aug; 67(2):328-338. PubMed ID: 28323124
[TBL] [Abstract][Full Text] [Related]
17. Extracellular vesicles derived from fat-laden hepatocytes undergoing chemical hypoxia promote a pro-fibrotic phenotype in hepatic stellate cells.
Hernández A; Reyes D; Geng Y; Arab JP; Cabrera D; Sepulveda R; Solis N; Buist-Homan M; Arrese M; Moshage H
Biochim Biophys Acta Mol Basis Dis; 2020 Oct; 1866(10):165857. PubMed ID: 32512191
[TBL] [Abstract][Full Text] [Related]
18. Cyclooxygenase-2 expression in hepatocytes attenuates non-alcoholic steatohepatitis and liver fibrosis in mice.
Motiño O; Agra N; Brea Contreras R; Domínguez-Moreno M; García-Monzón C; Vargas-Castrillón J; Carnovale CE; Boscá L; Casado M; Mayoral R; Valdecantos MP; Valverde ÁM; Francés DE; Martín-Sanz P
Biochim Biophys Acta; 2016 Sep; 1862(9):1710-23. PubMed ID: 27321932
[TBL] [Abstract][Full Text] [Related]
19. Inhibition of Secretin/Secretin Receptor Axis Ameliorates NAFLD Phenotypes.
Chen L; Wu N; Kennedy L; Francis H; Ceci L; Zhou T; Samala N; Kyritsi K; Wu C; Sybenga A; Ekser B; Dar W; Atkins C; Meadows V; Glaser S; Alpini G
Hepatology; 2021 Oct; 74(4):1845-1863. PubMed ID: 33928675
[TBL] [Abstract][Full Text] [Related]
20. Phytochemical gallic acid alleviates nonalcoholic fatty liver disease via AMPK-ACC-PPARa axis through dual regulation of lipid metabolism and mitochondrial function.
Zhang J; Zhang W; Yang L; Zhao W; Liu Z; Wang E; Wang J
Phytomedicine; 2023 Jan; 109():154589. PubMed ID: 36610145
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
